Third response in concurrent BTKi Cohort of azer-cel Trial
Open PDF
| Stock | Imugene Ltd (IMU.ASX) |
|---|---|
| Release Time | 27 Jul 2026, 9:55 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Imugene Reports Third Response in BTKi Cohort of azer-cel Trial
Key Points
- Third response achieved in concurrent BTKi cohort of azer-cel Phase 1b study
- Second FL patient in the cohort reports a partial response
- Both FL patients in the cohort responded to treatment with azer-cel and BTKi
Full Summary
Imugene Limited (ASX: IMU) reports additional patient data from the concurrent BTK inhibitor (BTKi) cohort of its ongoing azer-cel (azercabtagene zapreleucel) Phase 1b clinical trial. The third response in the cohort was achieved by a second Follicular Lymphoma (FL) patient, who had previously progressed on BTKi therapy. Both FL patients in the concurrent BTKi cohort have demonstrated a response to treatment with azer-cel and a BTKi. The trial aims to evaluate whether concurrent dosing of azer-cel with a BTKi can restore or enhance therapeutic activity in patients with B-cell malignancies who have developed resistance to BTKi therapy.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In